Scarica l'app Stockscreener
1.62
4.71%
-0.08
Aptevo Therapeutics Inc Borsa (APVO) Ultime notizie
Aptevo advances APVO-451 toward IND-enabling studies - BioWorld News
Aptevo Therapeutics (APVO) Advances Trispecific Therapies Amid C - GuruFocus
Aptevo advances trispecific cancer therapy manufacturing - Investing.com
Aptevo Advances Trispecific APVO451 Toward Clinical Development - accessnewswire.com
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development - Stock Titan
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development - Yahoo Finance
Aptevo Therapeutics (APVO) Edges Lower to $1.82 as Shares Hold Above $1.73 SupportFactor Timing - dars.gov.et
APVO StockImmuno-Oncology Company To Watch Petersburg (cK2qyfq7CG) - Mshale
Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial - Benzinga
Aptevo Therapeutics (NASDAQ: APVO) Registers 6.44M Shares for Holder Resale Following Warrant Exercises - kalkinemedia.com
Aptevo Therapeutics (APVO) Shares Fall Despite Roth Capital Opti - GuruFocus
Roth MKM Maintains Aptevo Therapeutics(APVO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Aptevo reports 93% clinical benefit rate in AML trial subset By Investing.com - Investing.com Nigeria
Aptevo reports 93% clinical benefit rate in AML trial subset By Investing.com - Investing.com South Africa
Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML - Yahoo Finance
Why is Aptevo Therapeutics stock slumping today? By Investing.com - Investing.com Canada
Why is Aptevo Therapeutics stock slumping today? By Investing.com - Investing.com UK
$Aptevo Therapeutics (APVO.US)$ [Strong][Smile][Heart][Rose][Leek] - Moomoo
Aptevo Therapeutics (APVO) Reports Promising AML Trial Results A - GuruFocus
Aptevo Reports Promising Mipletamig Data in TP53-Mutant AML - TipRanks
Aptevo reports 93% clinical benefit rate in AML trial subset By Investing.com - Investing.com India
Aptevo reports 93% clinical benefit rate in AML trial subset - Investing.com
Aptevo Reports Strong Mipletamig Results in TP53-Mutated AML - ACCESS Newswire
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML - FinancialContent
Aptevo Therapeutics Inc. SEC Filing (Sep 3, 2026) - Stock Titan
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML - Yahoo Finance
Aptevo Therapeutics Inc. (APVO) Peer Comparison – Compare with Others - Value Research
Foremost Clean Energy and Aptevo Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Times Herald-Record
Aptevo Therapeutics Inc. (APVO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Aptevo Therapeutics (APVO) quietly closes private funding round - Stock Titan
Aptevo (APVO) Momentum: Moves 10.07% Down to $2.41 for the Current Session; Next Test: the Price Remains Bounded by the Supplied Support and Resistance in the Latest ReadingHagopian Line - vinanet.vn
APVO: Focusing on Three Key Areas of Development - Yahoo Finance
Aptevo Shareholders Back Board, Auditor and Incentive Plan - TipRanks
Aptevo (NASDAQ: APVO) asks holders to approve dilutive warrant deal - Stock Titan
Roth MKM Maintains Aptevo Therapeutics(APVO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Weekly Recap: APVO H1 losses and Aug 13 financing via warrants, PIPE - TradingView
Aptevo Therapeutics (APVO): CVI and Heights disclose 6.3% warrant-based stake - Stock Titan
Aptevo Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Aptevo Therapeutics Inc.: Financial Data Forecasts Estimates and Expectations | AP8 | US03835L3069 - marketscreener.com
Form 8K Aptevo Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Aptevo Therapeutics Inc. 6M 2026: Net loss $(13.15M), Diluted EPS $(11.19) — 10-Q Summary - TradingView
Form 8K Aptevo Therapeutics Inc For: 14 August By Investing.com - Investing.com Canada
Aptevo APVO Reports Q2 2026 Update With $9.8 Million Cash - Quiver Quantitative
Form 8K Aptevo Therapeutics Inc For: 14 August By Investing.com - Investing.com UK
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results - ACCESS Newswire
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results - Yahoo Finance
Aptevo APVO Reports Q2 2026 Update With $9.8 Million Cash - Quiver Quantitative
Aptevo Therapeutics Raises Capital Through Warrant-Induced Financing - TipRanks
Aptevo raises $4.5 million through warrant and equity financing By Investing.com - Investing.com Nigeria
Aptevo Raises $4.5 Million Via Warrant Exercises and PIPE; Issues 5.6M Warrants at $4.03 - TradingView
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):